• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Financial Report: PPD

contractpharmaOctober 30, 2020

Tag: PPD , Financial Report , revenues

PPD

3Q Revenues: $1.2 billion (+21%)

3Q Earnings: $9.1 million (-45%)

YTD Revenues: $3.3 billion (+11%)

YTD Earnings: $58.1 million (+69%)

Comments: Clinical Development Services revenue was $1.0 billion in the quarter, up 19% and Laboratory Services revenue was $225.2 million, up 27%. Net authorizations of $1.2 billion, representing 33% growth over third quarter 2019 and resulting in a net book-to-bill ratio of 1.35x on a historical basis. Ending backlog of $7.9 billion, representing 16% growth over third quarter 2019.

Previous:TherapeutAix Expands R&D Network

Next:Avomeen Names SVP of Lab Operations

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Financial Report: PPD | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

2-Nitro-p-phenylene diamine（2NPPD）(5307-14-2)

2-Nitro-p-phenylene diamine（2NPPD）(5307-14-2)
Protopanaxadiol(APPD)-98%

Protopanaxadiol(APPD)-98%
P-PHENYL DIISOCYANATE（PPDI）99PCT

P-PHENYL DIISOCYANATE（PPDI）99PCT
AMPPD

AMPPD
O-CHLORO-P-PHENYLENE DIAMINE SULFATE (OCPPDS)

O-CHLORO-P-PHENYLENE DIAMINE SULFATE (OCPPDS)
Protopanaxadiol(APPD)-40%

Protopanaxadiol(APPD)-40%
P-phenylenediamine(PPD) (106-50-3)

P-phenylenediamine(PPD) (106-50-3)
P-PHENYLENE DIAMINE WHITE FLAKE (PPD)

P-PHENYLENE DIAMINE WHITE FLAKE (PPD)
2-NITRO-P-PHENYLENE DIAMINE (2NPPD)

2-NITRO-P-PHENYLENE DIAMINE (2NPPD)
P-PHENYLENE DIAMINE SULFATE (PPDS)

P-PHENYLENE DIAMINE SULFATE (PPDS)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service